PH26545A - Anhydrous crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide - Google Patents
Anhydrous crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide Download PDFInfo
- Publication number
- PH26545A PH26545A PH36441A PH36441A PH26545A PH 26545 A PH26545 A PH 26545A PH 36441 A PH36441 A PH 36441A PH 36441 A PH36441 A PH 36441A PH 26545 A PH26545 A PH 26545A
- Authority
- PH
- Philippines
- Prior art keywords
- sodium salt
- oxindole
- carboxamide
- chloro
- thenoyl
- Prior art date
Links
- 159000000000 sodium salts Chemical class 0.000 title claims description 15
- IGPDWKCUDHIIRL-UHFFFAOYSA-N 5-chloro-2-oxo-3-[oxo(thiophen-2-yl)methyl]-3H-indole-1-carboxamide Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)C1C(=O)C1=CC=CS1 IGPDWKCUDHIIRL-UHFFFAOYSA-N 0.000 title description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- -1 2-thenoyl Chemical group 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 2
- UYINJAQCJCYCGO-UHFFFAOYSA-N 2-oxo-3h-indole-1-carboxamide Chemical compound C1=CC=C2N(C(=O)N)C(=O)CC2=C1 UYINJAQCJCYCGO-UHFFFAOYSA-N 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- NOJNFULGOQGBKB-UHFFFAOYSA-M sodium;3-[3-tert-butylsulfanyl-1-[[4-(6-ethoxypyridin-3-yl)phenyl]methyl]-5-[(5-methylpyridin-2-yl)methoxy]indol-2-yl]-2,2-dimethylpropanoate Chemical compound [Na+].C1=NC(OCC)=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(OCC=3N=CC(C)=CC=3)C=C2C(SC(C)(C)C)=C1CC(C)(C)C([O-])=O NOJNFULGOQGBKB-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1987/000201 WO1988005656A1 (en) | 1987-02-02 | 1987-02-02 | Anhydrous, crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26545A true PH26545A (en) | 1992-08-19 |
Family
ID=22202263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH36441A PH26545A (en) | 1987-02-02 | 1988-02-01 | Anhydrous crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide |
Country Status (42)
| Country | Link |
|---|---|
| US (1) | US5036099A (pt) |
| EP (1) | EP0277738B1 (pt) |
| JP (1) | JPS63201184A (pt) |
| KR (1) | KR900001422B1 (pt) |
| CN (1) | CN1022324C (pt) |
| AP (1) | AP52A (pt) |
| AR (1) | AR243182A1 (pt) |
| AT (1) | ATE73800T1 (pt) |
| AU (1) | AU587736B2 (pt) |
| BG (1) | BG51042A3 (pt) |
| CA (1) | CA1335590C (pt) |
| CS (2) | CS265250B2 (pt) |
| CY (1) | CY1775A (pt) |
| DD (1) | DD267490A5 (pt) |
| DE (1) | DE3869149D1 (pt) |
| DK (1) | DK44888A (pt) |
| EC (1) | ECSP941082A (pt) |
| ES (1) | ES2032955T3 (pt) |
| FI (1) | FI89598C (pt) |
| GR (1) | GR3004200T3 (pt) |
| HK (1) | HK132695A (pt) |
| IE (1) | IE60000B1 (pt) |
| IL (1) | IL85277A (pt) |
| IN (1) | IN171799B (pt) |
| IS (1) | IS1533B (pt) |
| LV (1) | LV10252B (pt) |
| MA (1) | MA21171A1 (pt) |
| MY (1) | MY102737A (pt) |
| NO (1) | NO170581C (pt) |
| NZ (1) | NZ223373A (pt) |
| OA (1) | OA08710A (pt) |
| PH (1) | PH26545A (pt) |
| PL (1) | PL149550B1 (pt) |
| PT (1) | PT86675B (pt) |
| RO (1) | RO105052B1 (pt) |
| RU (1) | RU2011381C1 (pt) |
| SG (1) | SG27994G (pt) |
| SI (1) | SI8810183A8 (pt) |
| UA (1) | UA25898A1 (pt) |
| WO (1) | WO1988005656A1 (pt) |
| YU (1) | YU46766B (pt) |
| ZA (1) | ZA88679B (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861794A (en) * | 1988-04-13 | 1989-08-29 | Pfizer Inc. | 3-substituted-2-oxindole-1-carboxamides as inhibitors of interleukin-1 biosynthesis |
| US4853409A (en) * | 1988-04-13 | 1989-08-01 | Pfizer Inc. | 3-substituted-2-oxindole-1-carboxamides for suppressing T-cell function |
| DE68923673T2 (de) * | 1988-10-18 | 1996-01-18 | Pfizer | Prodrogen von antiinflammatorischen 3-Acyl-2-oxindol-1-carboxamiden. |
| SK590689A3 (en) * | 1988-10-18 | 1996-03-06 | Pfizer | 3-aryl-2-oxindole-1-carboxamides and method of their preparation |
| US5059693A (en) * | 1989-10-06 | 1991-10-22 | Pfizer Inc. | Process for making 3-aroyl-2-oxindole-1-carboxamides |
| US5006547A (en) * | 1990-03-19 | 1991-04-09 | Pfizer Inc. | Tenidap as an inhibitor of the release of elastase by neutrophils |
| US5008283A (en) * | 1990-03-19 | 1991-04-16 | Pfizer Inc. | Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase |
| US5122534A (en) * | 1991-02-08 | 1992-06-16 | Pfizer Inc. | Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides |
| DE4111305C2 (de) * | 1991-04-08 | 1994-12-01 | Mack Chem Pharm | Pharmazeutische Zubereitung zur rektalen Applikation, die ein 2-Oxindol-l-carboxamid-derivat enthält |
| WO1997022605A1 (en) * | 1995-12-19 | 1997-06-26 | Pfizer Inc. | Stable, long acting salts of indole derivatives for the treatment of joint diseases |
| EP0826685A1 (en) * | 1996-08-21 | 1998-03-04 | Pfizer Inc. | Stable, long acting salts of carboxamides for the treatment of joint disease |
| DE19854355A1 (de) * | 1998-11-25 | 2000-05-31 | Bayer Ag | Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
| US7407195B2 (en) | 2004-04-14 | 2008-08-05 | William Berson | Label for receiving indicia having variable spectral emissivity values |
| US7651031B2 (en) | 2004-10-25 | 2010-01-26 | William Berson | Systems and methods for reading indicium |
| US7728726B2 (en) * | 2005-01-14 | 2010-06-01 | William Berson | Radio frequency identification labels |
| US7931413B2 (en) * | 2005-01-14 | 2011-04-26 | William Berson | Printing system ribbon including print transferable circuitry and elements |
| US7619520B2 (en) * | 2005-01-14 | 2009-11-17 | William Berson | Radio frequency identification labels and systems and methods for making the same |
| US7621451B2 (en) * | 2005-01-14 | 2009-11-24 | William Berson | Radio frequency identification labels and systems and methods for making the same |
| KR20200085285A (ko) | 2017-11-02 | 2020-07-14 | 애커러트 메디컬 테라퓨틱스 엘티디. | 필터가 내장된 색전술용 카테터 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3767653A (en) * | 1971-06-28 | 1973-10-23 | Squibb & Sons Inc | Thiazines |
| GB1532413A (en) * | 1974-12-23 | 1978-11-15 | Union International Co Ltd | Chenodeoxycholic acid |
| DE2613346C3 (de) * | 1976-03-29 | 1981-07-23 | Diamalt AG, 8000 München | Monoklin kristalline Chenodesoxycholsäure und Verfahren zu ihrer Herstellung |
| ATE63543T1 (de) * | 1984-02-07 | 1991-06-15 | Pfizer | 2-oxindolzwischenprodukte. |
| US4556672A (en) * | 1984-03-19 | 1985-12-03 | Pfizer Inc. | 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents |
| DE3579716D1 (de) * | 1984-03-19 | 1990-10-25 | Pfizer | Verfahren zur herstellung von 2-oxindole-1-carboxamiden und deren zwischenprodukte. |
| US4569942A (en) * | 1984-05-04 | 1986-02-11 | Pfizer Inc. | N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents |
-
1987
- 1987-02-02 RO RO140907A patent/RO105052B1/ro unknown
- 1987-02-02 WO PCT/US1987/000201 patent/WO1988005656A1/en active IP Right Grant
- 1987-02-02 US US07/460,137 patent/US5036099A/en not_active Expired - Lifetime
- 1987-02-02 UA UA4614718A patent/UA25898A1/uk unknown
-
1988
- 1988-01-25 ES ES88300561T patent/ES2032955T3/es not_active Expired - Lifetime
- 1988-01-25 AT AT88300561T patent/ATE73800T1/de not_active IP Right Cessation
- 1988-01-25 EP EP88300561A patent/EP0277738B1/en not_active Expired - Lifetime
- 1988-01-25 DE DE8888300561T patent/DE3869149D1/de not_active Expired - Fee Related
- 1988-01-27 IN IN67/DEL/88A patent/IN171799B/en unknown
- 1988-01-28 AP APAP/P/1988/000081A patent/AP52A/en active
- 1988-01-29 CA CA000557662A patent/CA1335590C/en not_active Expired - Fee Related
- 1988-01-29 DK DK044888A patent/DK44888A/da not_active Application Discontinuation
- 1988-02-01 NZ NZ223373A patent/NZ223373A/xx unknown
- 1988-02-01 OA OA59273A patent/OA08710A/xx unknown
- 1988-02-01 KR KR1019880000876A patent/KR900001422B1/ko not_active IP Right Cessation
- 1988-02-01 BG BG082816A patent/BG51042A3/xx unknown
- 1988-02-01 MA MA21408A patent/MA21171A1/fr unknown
- 1988-02-01 AR AR88309983A patent/AR243182A1/es active
- 1988-02-01 PT PT86675A patent/PT86675B/pt not_active IP Right Cessation
- 1988-02-01 PL PL1988270415A patent/PL149550B1/pl unknown
- 1988-02-01 SI SI8810183A patent/SI8810183A8/sl not_active IP Right Cessation
- 1988-02-01 YU YU18388A patent/YU46766B/sh unknown
- 1988-02-01 DD DD88312599A patent/DD267490A5/de not_active IP Right Cessation
- 1988-02-01 IL IL8527788A patent/IL85277A/en not_active IP Right Cessation
- 1988-02-01 ZA ZA88679A patent/ZA88679B/xx unknown
- 1988-02-01 AU AU11160/88A patent/AU587736B2/en not_active Ceased
- 1988-02-01 PH PH36441A patent/PH26545A/en unknown
- 1988-02-02 JP JP63022675A patent/JPS63201184A/ja active Granted
- 1988-02-02 CS CS88648A patent/CS265250B2/cs unknown
- 1988-02-02 MY MYPI88000091A patent/MY102737A/en unknown
- 1988-02-02 IS IS3309A patent/IS1533B/is unknown
- 1988-02-02 CN CN88100555A patent/CN1022324C/zh not_active Expired - Fee Related
- 1988-09-29 NO NO88884329A patent/NO170581C/no not_active IP Right Cessation
-
1989
- 1989-07-18 IE IE26988A patent/IE60000B1/en not_active IP Right Cessation
- 1989-08-01 FI FI893647A patent/FI89598C/fi not_active IP Right Cessation
- 1989-08-01 RU SU894614718A patent/RU2011381C1/ru not_active IP Right Cessation
-
1991
- 1991-11-22 CS CS913541A patent/CS354191A3/cs unknown
-
1992
- 1992-03-31 GR GR920400571T patent/GR3004200T3/el unknown
-
1993
- 1993-11-15 LV LVP-93-1225A patent/LV10252B/xx unknown
-
1994
- 1994-02-22 SG SG27994A patent/SG27994G/en unknown
- 1994-05-05 EC EC1994001082A patent/ECSP941082A/es unknown
-
1995
- 1995-08-24 HK HK132695A patent/HK132695A/xx not_active IP Right Cessation
-
1996
- 1996-04-05 CY CY177596A patent/CY1775A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP52A (en) | Anhydrous, crystalline sodium salt of 5-chloro-3-(2-thenoy) -2-oxindole-1-carboxamide. | |
| AU2002366383B2 (en) | Polymorphs of clopidogrel hydrogensulfate | |
| RU2177000C2 (ru) | Способ приготовления амлодипин бензолсульфоната | |
| JP2007302658A (ja) | イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法 | |
| JP2001500878A (ja) | オランザピン二水和物ｄ | |
| EP1483269A1 (en) | Racemization and enantiomer separation of clopidogrel | |
| NO312514B1 (no) | Mesylat-dihydratsalter av 5-(2-(4-(1,2-benzisotiazol-3-yl)-1- piperazinyl)-etyl)-6-klor-1,3-dihydro-2(1H)-indol-2-on(ziprazidone), og farmasöytisk blanding for behandling av enpsykotisk forstyrrelse | |
| ZA200509155B (en) | Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same | |
| CA2499819A1 (en) | Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these | |
| EP0703915B1 (en) | Xamoneline tartrate | |
| KR101145433B1 (ko) | 로시글리타존 말레이트의 다형을 제조하는 방법 | |
| CN103864756B (zh) | 丁二磺酸达比加群酯及其制备方法和用途 | |
| WO2005021481A1 (en) | N, n’-dibenzyl ethylenediamine salt pf 2-(alpha-hidroxypentyl) benzoic acid and its preparing process and usage | |
| CN103539779B (zh) | 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途 | |
| JP3931884B2 (ja) | 錠剤の製造方法 | |
| BG62228B2 (bg) | Безводна кристална натриева сол на 5-хлор-3-(2-теноил)-2- оксиндол-1-карбоксамид | |
| HU211140A9 (hu) | Az 5-klór-3-(2*tenoil)-2-oxindol-1-karboxamid vízmentes, kristályos nátriumsója | |
| JP3532558B2 (ja) | Ｌ−アスパラギン酸カルシウム３水和物結晶の製造方法 | |
| JPS62242667A (ja) | ベンジルイソキノリン誘導体 | |
| JP2006298943A (ja) | 結晶性ｌ−アスパラギン酸カルシウムの製造方法 | |
| JPS62192365A (ja) | ベンズイミダゾ−ル化合物 | |
| JPH08807B2 (ja) | 新規ホモベラトリルアミン誘導体及びその製造法 |